drugset / Trial / NCT07048353
CD30 CAR-T in the Treatment of CD30 Positive Lymphoma
Phase 0
Not yet recruiting
15 enrolled
Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
First Affiliated Hospital of Guangxi Medical University · collabShanxi Bethune Hospital · collabTongji Hospital Affiliated to Tongji Medical College of HUST · collabWuhan Central Hospital · collabYichang Central People's Hospital · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The is a prospective, open-label, dose-climbing multicenter clinical study assessing the efficacy and safety of CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit 15 subjects with r/r CD30+ lymphoma。
Timeline
- Start
- 2025-07-28
- Primary completion
- 2029-07-28
- Completion
- 2029-07-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | chimeric antigen receptor gene modified T cells | Cell therapy | — | Intravenous |